Bullzeye FinancialAnthem Biosciences Ltd.
NSE: ANTHEM · Healthcare
Severe Q1 revenue collapse (22.58% YoY, 31.54% QoQ) with vague management recovery guidance, momentum divergence (RSI 41.51, volume 38% of…
Bullish EMA stack intact, strong net cash position (₹1,720 crores), 60% order book secured, and management guidance of Q2 recovery with margin resilience (39.6% EBITDA) suggest temporary soft quarter within longer-term uptrend.
Q1 revenue decline of 31.54% QoQ far exceeds seasonal patterns; 'deferred customer deliveries' lacks specificity on timing or customer viability; RSI 41.51 and 38% volume signal evaporating conviction despite intact EMA structure.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bearish 28 Sep 2026 → now Scores 28 Oct 2026₹851.10 → ₹851.10 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →